Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis

Gibson, 2003, Pathophysiology and management of pulmonary infections in cystic fibrosis, Am J Respir Crit Care Med, 168, 918, 10.1164/rccm.200304-505SO Lipuma, 2010, The changing microbial epidemiology in cystic fibrosis, Clin Microbiol Rev, 23, 299, 10.1128/CMR.00068-09 Hauser, 2011, Clinical significance of microbial infection and adaptation in cystic fibrosis, Clin Microbiol Rev, 24, 29, 10.1128/CMR.00036-10 Flume, 2007, Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health, Am J Respir Crit Care Med, 176, 957, 10.1164/rccm.200705-664OC Heijerman, 2009, Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus, J Cyst Fibros, 8, 295, 10.1016/j.jcf.2009.04.005 Moskowitz, 2008, Shifting patterns of inhaled antibiotic use in cystic fibrosis, Pediatr Pulmonol, 43, 874, 10.1002/ppul.20873 Geller, 2009, Aerosol antibiotics in cystic fibrosis, Respir Care, 54, 658, 10.4187/aarc0537 Sawicki, 2009, High treatment burden in adults with cystic fibrosis: challenges to disease self-management, J Cyst Fibros, 8, 91, 10.1016/j.jcf.2008.09.007 DiMatteo, 2004, Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research, Med Care, 42, 200, 10.1097/01.mlr.0000114908.90348.f9 Arias Llorente, 2008, Treatment compliance in children and adults with cystic fibrosis, J Cyst Fibros, 7, 359, 10.1016/j.jcf.2008.01.003 Czajkowski, 1987, Medical compliance and coping with cystic fibrosis, J Child Psychol Psychiatry, 28, 311, 10.1111/j.1469-7610.1987.tb00213.x Kettler, 2002, Determinants of adherence in adults with CF, Thorax, 57, 459, 10.1136/thorax.57.5.459 Eakin, 2011, Longitudinal association between medication adherence and lung health in people with cystic fibrosis, J Cyst Fibros, 10, 258, 10.1016/j.jcf.2011.03.005 Rau, 2005, Determinants of patient adherence to an aerosol regimen, Respir Care, 50, 1346 Milgrom, 1996, Noncompliance and treatment failure in children with asthma, J Allergy Clin Immunol, 98, 1051, 10.1016/S0091-6749(96)80190-4 Briesacher, 2011, Adherence with tobramycin inhaled solution and health care utilization, BMC Pulm Med, 11, 5, 10.1186/1471-2466-11-5 Kesser, 2009, New aerosol delivery devices for cystic fibrosis, Respir Care, 54, 754, 10.4187/002013209790983250 Geller, 2008, The science of aerosol delivery in cystic fibrosis, Pediatr Pulmonol, 43, S5, 10.1002/ppul.20860 Mendelman, 1985, Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum, Am Rev Respir Dis, 132, 761 King, 2010, In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis, Antimicrob Agents Chemother, 54, 143, 10.1128/AAC.00248-09 Ramsey, 1993, Efficacy of aerosolized tobramycin in patients with cystic fibrosis, N Engl J Med, 328, 1740, 10.1056/NEJM199306173282403 Chuchalin, 2007, A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study, Paediatr Drugs, 9, 21, 10.2165/00148581-200709001-00004 Coates, 2008, Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis, Pediatr Pulmonol, 4, 753, 10.1002/ppul.20850 Dupont, 2008, A randomized, placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection, J Cyst Fibros, 7, S26, 10.1016/S1569-1993(08)60099-5 Okusanya, 2009, Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection, Antimicrob Agents Chemother, 53, 3847, 10.1128/AAC.00872-08 Bruinenberg, 2008, The effect of once-a-day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization, Pediatr Pulmonol, 43, 344 Westerman, 2007, Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study, J Cyst Fibros, 6, 284, 10.1016/j.jcf.2006.10.010 Geller, 2011, Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere(tm) technology, J Aerosol Med Pulm Drug Deliv, 24, 175, 10.1089/jamp.2010.0855 Newhouse, 2003, Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers, Chest, 124, 360, 10.1378/chest.124.1.360 Geller, 2007, A novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety, Pediatr Pulmonol, 42, 307, 10.1002/ppul.20594 Konstan, 2011, Tobramycin inhalation powder for Pseudomonas aeruginosa infection in cystic fibrosis: the EVOLVE trial, Pediatr Pulmonol, 46, 230, 10.1002/ppul.21356 Konstan, 2011, Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial, J Cyst Fibros, 10, 54, 10.1016/j.jcf.2010.10.003 Stass, 2008, Pharmacokinetics of ciprofloxacin PulmoSphere® inhalational powder, J Cyst Fibros, 7, S26, 10.1016/S1569-1993(08)60100-9 Tiddens, 2006, Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older, J Aerosol Med, 19, 456, 10.1089/jam.2006.19.456 Trapnell, 2011, Fosfomycin/tobramycin for inhalation in cystic fibrosis patients with Pseudomonas airway infection, Am J Respir Crit Care Med Yang, 2010, Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis, Pharm Res, 27, 151, 10.1007/s11095-009-9991-2 Gibson, 2006, Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis, Pediatr Pulmonol, 41, 656, 10.1002/ppul.20429 Geller, 2011, Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa, Am J Respir Crit Care Med, 183, 1510, 10.1164/rccm.201008-1293OC Hubert, 2009, Pharmacokinetics and safety of tobramycin administered by the PARI eFlow® rapid nebulizer in cystic fibrosis, J Cyst Fibros, 8, 332, 10.1016/j.jcf.2009.07.001 Lenney, 2011, Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects, J Cyst Fibros, 10, 9, 10.1016/j.jcf.2010.08.019 Denyer, 2010, The Adaptive Aerosol Delivery (AAD) technology: past, present, and future, J Aerosol Med Pulm Drug Deliv, 23, S1, 10.1089/jamp.2009.0791 Brand, 2000, Total deposition of therapeutic particles during spontaneous and controlled inhalations, J Pharm Sci, 89, 724, 10.1002/(SICI)1520-6017(200006)89:6<724::AID-JPS3>3.0.CO;2-B McCormack, 2011, A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis, J Cyst Fibros, 10, 343, 10.1016/j.jcf.2011.04.006 Bennett, 2005, Controlled inhalation of aerosolized therapeutics, Expert Opin Drug Deliv, 2, 763, 10.1517/17425247.2.4.763 Denyer, 2010, Adherence monitoring in drug delivery, Expert Opin Drug Deliv, 7, 1127, 10.1517/17425247.2010.517520 Cystic Fibrosis Trust. Antibiotic treatment for cystic fibrosis, 3rd edn. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group; 2009. McNamara, 2009, Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis, J Cyst Fibros, 8, 258, 10.1016/j.jcf.2009.04.006 Meichenbaum, 1987 Gibson, 1988, Perspective in parental coping with a chronically ill child: the case of cystic fibrosis, Issues Compr Pediatr Nurs, 11, 33, 10.3109/01460868809026829 Madge, 2006, 'Challenges for nurses', vol. 34, 286 Burker, 2004, Psychological and educational factors: better predictors of work status than FEV1 in adults with CF, Pediatr Pulmonol, 38, 413, 10.1002/ppul.20090 Moise, 1987, Correlates of psychosocial adjustment among young adults with cystic fibrosis, J Dev Behav Pediatr, 8, 141, 10.1097/00004703-198706000-00003 Oxley, 2005, How a clinical psychologist manages the problems of adults with cystic fibrosis, J R Soc Med, 98, 37 Hafetz, 2010, Child and parent perceptions of monitoring in chronic illness management: a qualitative study, Child Care Health Dev, 36, 655, 10.1111/j.1365-2214.2010.01102.x Dziuban, 2010, Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis, Pediatr Pulmonol, 45, 450, 10.1002/ppul.21195 Lehane, 2007, Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper, Int J Nurs Stud, 44, 1468, 10.1016/j.ijnurstu.2006.07.010 Modi, 2006, Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way?, J Pediatr Psychol, 31, 846, 10.1093/jpepsy/jsj096 Abbott, 1995, Different perceptions of disease severity and self care between patients with cystic fibrosis, their close companions, and physician, Thorax, 50, 794, 10.1136/thx.50.7.794 Duff, 2010, Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it, J Cyst Fibros, 9, 455, 10.1016/j.jcf.2010.08.012 Bender, 2003, Adherence intervention research: what have we learned and what do we do next?, J Allergy Clin Immunol, 112, 489, 10.1016/S0091-6749(03)01718-4 Bender, 2000, Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT, Ann Allergy Asthma Immunol, 85, 416, 10.1016/S1081-1206(10)62557-4 Daniels, 2011, Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers, Chest, 140, 425, 10.1378/chest.09-3074 Elliott, 2005, Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence, Ann Pharmacother, 39, 508, 10.1345/aph.1E398 McClimans, 2011, Health policy, patient-centred care and clinical ethics, J Eval Clin Pract, 17, 913, 10.1111/j.1365-2753.2011.01726.x Duff, 2010, Motivational interviewing for adherence problems in cystic fibrosis: state of the art review, Pediatr Pulmonol, 45, 211, 10.1002/ppul.21103 Hides, 2011, Does the addition of integrated cognitive behaviour therapy and motivational interviewing improve the outcomes of standard care for young people with comorbid depression and substance misuse?, Med J Aust, 195, S31, 10.5694/j.1326-5377.2011.tb03263.x Fowler, 2011, Adherence and competence assessment in studies of CBT for psychosis: current status and future directions, Epidemiol Psychiatr Sci, 20, 121, 10.1017/S2045796011000199 Brocklehurst, 2010, Personal construct psychology: a theory to help understand professional development, a philosophy to support it, Prim Dent Care, 17, 179, 10.1308/135576110792936140 Nezu, 2006, Problem solving to promote treatment adherence, 135 Melnyk, 2001, Coping in parents of children who are chronically ill: strategies for assessment and intervention, Pediatr Nurs, 27, 547